The risk assessment of relapse among newly enrolled participants in methadone maintenance treatment: A group-LASSO based Bayesian network study.
Bayesian networks
methadone maintenance treatment
relapse
risk assessment
treatment duration
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
08
2022
accepted:
23
12
2022
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
Relapse is a great barrier to improving the effectiveness of methadone maintenance treatment (MMT). Participants with different treatment durations could vary in their compliance with MMT, which may lead to different levels of relapse risk. This study aims to identify the risk factors for relapse and assess the relapse risk of MMT participants of different treatment durations. This retrospective study used data collected from seven MMT clinics in Guangdong Province, China, from January 2010 to April 2017. Newly enrolled participants who received 6 ( The results showed that participants who received 6-month treatment had a lower relapse rate (32.0%) than those of 12-month treatment (39.0%, It is necessary to implement targeted interventions and education based on the treatment durations of participants to decrease the relapse rate. Meanwhile, those about HIV/sexually transmitted infection prevention and anti-narcotics should be held in the whole process.
Sections du résumé
Background
Relapse is a great barrier to improving the effectiveness of methadone maintenance treatment (MMT). Participants with different treatment durations could vary in their compliance with MMT, which may lead to different levels of relapse risk. This study aims to identify the risk factors for relapse and assess the relapse risk of MMT participants of different treatment durations.
Method
This retrospective study used data collected from seven MMT clinics in Guangdong Province, China, from January 2010 to April 2017. Newly enrolled participants who received 6 (
Results
The results showed that participants who received 6-month treatment had a lower relapse rate (32.0%) than those of 12-month treatment (39.0%,
Conclusion
It is necessary to implement targeted interventions and education based on the treatment durations of participants to decrease the relapse rate. Meanwhile, those about HIV/sexually transmitted infection prevention and anti-narcotics should be held in the whole process.
Identifiants
pubmed: 36733286
doi: 10.3389/fpubh.2022.1032217
pmc: PMC9886899
doi:
Substances chimiques
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1032217Informations de copyright
Copyright © 2023 Tang, Fan, Wang, Wang, Chen, Xu and Ling.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Pol Arch Intern Med. 2021 Apr 29;131(4):345-355
pubmed: 33667051
Eur J Epidemiol. 2022 Jan;37(1):1-10
pubmed: 35025022
Addiction. 2007 May;102(5):771-7
pubmed: 17506154
Harm Reduct J. 2019 May 27;16(1):34
pubmed: 31133016
Drug Alcohol Depend. 2002 Jul 1;67(2):125-37
pubmed: 12095662
Drug Alcohol Rev. 2015 Nov;34(6):645-53
pubmed: 25867927
J Abnorm Psychol. 2016 Oct;125(7):946-959
pubmed: 27537477
Subst Abuse Treat Prev Policy. 2017 Jun 8;12(1):31
pubmed: 28595642
Drug Alcohol Depend. 2014 Dec 1;145:87-93
pubmed: 25448082
J Opioid Manag. 2007 Jan-Feb;3(1):27-34
pubmed: 17367092
Haematologica. 2001 Sep;86(9):941-50
pubmed: 11532622
Subst Abuse Treat Prev Policy. 2021 Feb 1;16(1):13
pubmed: 33526066
J Addict Med. 2015 Nov-Dec;9(6):440-6
pubmed: 26484843
Subst Use Misuse. 2011;46(9):1190-8
pubmed: 21417558
Psychopathology. 2002 Mar-Jun;35(2-3):171-5
pubmed: 12145505
Drug Alcohol Depend. 2021 Feb 1;219:108466
pubmed: 33421801
Yonsei Med J. 2018 May;59(3):397-405
pubmed: 29611402
Rev Med Chil. 2008 Feb;136(2):169-78
pubmed: 18483670
Ir J Med Sci. 2016 May;185(2):433-41
pubmed: 26026953
BMC Med Res Methodol. 2017 Dec 6;17(1):162
pubmed: 29207961
Front Psychiatry. 2022 Oct 13;13:971825
pubmed: 36311529
Int J Neuropsychopharmacol. 2008 Aug;11(5):641-53
pubmed: 18205978
Harm Reduct J. 2017 Sep 7;14(1):63
pubmed: 28882155
PLoS One. 2015 Apr 14;10(4):e0123687
pubmed: 25875531
BMJ. 2014 May 02;348:g2979
pubmed: 25134102
J Subst Abuse Treat. 2015 Oct;57:75-80
pubmed: 25997674
Southeast Asian J Trop Med Public Health. 2016 Mar;47(2):287-98
pubmed: 27244967
BMC Neurol. 2016 Aug 18;16(1):145
pubmed: 27538517
Evid Based Med Public Health. 2016;2:
pubmed: 27066590
BMC Nephrol. 2020 May 5;21(1):162
pubmed: 32370757
Subst Abuse Treat Prev Policy. 2019 Sep 18;14(1):39
pubmed: 31533764
Cochrane Database Syst Rev. 2003;(3):CD002208
pubmed: 12917925
Int J Environ Res Public Health. 2019 Aug 06;16(15):
pubmed: 31390750
Drug Alcohol Depend. 2005 Dec 12;80(3):329-35
pubmed: 15964714
Ir J Psychol Med. 2012 Jan;29(2):72-79
pubmed: 30199951
Front Pharmacol. 2020 Apr 03;11:401
pubmed: 32308624
Addict Behav. 2014 Jan;39(1):22-9
pubmed: 24090627
Liver Transpl. 2007 Nov;13(11 Suppl 2):S59-64
pubmed: 17969089
Front Immunol. 2022 Feb 18;13:765839
pubmed: 35250969
PLoS One. 2020 Jan 29;15(1):e0228152
pubmed: 31995601
Subst Abuse. 2016 Apr 10;10:9-18
pubmed: 27103815
PLoS One. 2013 Jun 20;8(6):e66787
pubmed: 23818964
Drug Alcohol Depend. 2018 Nov 1;192:94-97
pubmed: 30243145
Curr Opin Psychiatry. 2019 Jul;32(4):282-287
pubmed: 30893091
J Transl Med. 2012 May 14;10:90
pubmed: 22583678
Am J Addict. 2020 May;29(3):174-175
pubmed: 32281130
PLoS One. 2015 Oct 20;10(10):e0139942
pubmed: 26484772